First Personal Financial Services Grows Stake in Haemonetics Co. (NYSE:HAE)

First Personal Financial Services raised its position in Haemonetics Co. (NYSE:HAE) by 5.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,798 shares of the medical instruments supplier’s stock after acquiring an additional 575 shares during the quarter. First Personal Financial Services’ holdings in Haemonetics were worth $893,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. TFO Wealth Partners LLC increased its position in shares of Haemonetics by 29,450.0% during the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 589 shares during the last quarter. Covestor Ltd boosted its stake in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 438 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Haemonetics during the 1st quarter valued at $86,000. Headlands Technologies LLC bought a new stake in shares of Haemonetics during the 1st quarter valued at $114,000. Finally, Central Pacific Bank Trust Division purchased a new stake in shares of Haemonetics in the 1st quarter worth $139,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Haemonetics

In other news, EVP Anila Lingamneni sold 2,136 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Anila Lingamneni sold 2,136 shares of Haemonetics stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the transaction, the executive vice president now owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. The disclosure for this sale can be found here. Insiders own 1.80% of the company’s stock.

Haemonetics Price Performance

Shares of Haemonetics stock traded up $0.23 on Friday, hitting $75.61. 667,648 shares of the company traded hands, compared to its average volume of 530,800. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The business has a 50-day simple moving average of $83.28 and a 200 day simple moving average of $83.78. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.50 and a current ratio of 2.56. The stock has a market capitalization of $3.85 billion, a P/E ratio of 33.02, a price-to-earnings-growth ratio of 1.64 and a beta of 0.29.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The company had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same quarter in the prior year, the firm posted $1.05 earnings per share. The business’s revenue was up 8.0% on a year-over-year basis. Research analysts expect that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on HAE. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Barrington Research increased their target price on shares of Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Citigroup lowered their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. Finally, Needham & Company LLC upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a research report on Wednesday, June 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $107.50.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.